Search Results - Tadashi Matsushita
- Showing 1 - 20 results of 24
- Go to Next Page
-
1
-
2
-
3
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa by Steven R. Lentz, S. Ehrenforth, Faraizah Abdul Karim, Tadashi Matsushita, Karin Weldingh, Jerzy Windyga, Johnny Mahlangu
Published 2014Artigo -
4
Immunofluorescence Analysis of Neutrophil Nonmuscle Myosin Heavy Chain-A in MYH9 Disorders: Association of Subcellular Localization with MYH9 Mutations by Shinji Kunishima, Tadashi Matsushita, Tetsuhito Kojima, Masahiro Sako, Fumihiro Kimura, Eun‐Kyeong Jo, Chikako Inoue, Tadashi Kamiya, Hidehiko Saito
Published 2003Artigo -
5
-
6
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors by Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Published 2017Artigo -
7
Structural and functional insights into S-thiolation of human serum albumins by Fumie Nakashima, Takahiro Shibata, Kohei Kamiya, Jun Yoshitake, Ryosuke Kikuchi, Tadashi Matsushita, Isao Ishii, Juan Antonio Giménez‐Bastida, Claus Schneider, Kôji Uchida
Published 2018Artigo -
8
-
9
Complete antithrombin deficiency in mice results in embryonic lethality by Kazuhiro Ishiguro, Tetsuhito Kojima, Kenji Kadomatsu, Yukiko Nakayama, Akira Takagi, Misao Suzuki, Naoki Takeda, Masafumi Ito, Koji Yamamoto, Tadashi Matsushita, Kazuo Kusugami, Takashi Muramatsu, Hidehiko Saito
Published 2000Artigo -
10
Syndecan-4 Deficiency Leads to High Mortality of Lipopolysaccharide-injected Mice by Kazuhiro Ishiguro, Kenji Kadomatsu, Tetsuhito Kojima, Hisako Muramatsu, Mitsunori Iwase, Yasunobu Yoshikai, Masamitsu Yanada, Koji Yamamoto, Tadashi Matsushita, Masahiko Nishimura, Kazuo Kusugami, Hidehiko Saito, Takashi Muramatsu
Published 2001Artigo -
11
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis by Bethany Samuelson Bannow, Michael Recht, Claude Négrier, Cédric Hermans, Erik Berntorp, Hermann Eichler, Maria Elisa Mancuso, Robert Klamroth, Jamie O’Hara, Elena Santagostino, Tadashi Matsushita, Craig M. Kessler
Published 2019Revisão -
12
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial by Peter W. Collins, Guy Young, Karin Knobe, Faraizah Abdul Karim, Pantep Angchaisuksiri, Claus Banner, Türkiz Gursel, Johnny Mahlangu, Tadashi Matsushita, Eveline P. Mauser‐Bunschoten, Johannes Oldenburg, Christopher Walsh, Claude Négrier
Published 2014Artigo -
13
Thrombosis from a Prothrombin Mutation Conveying Antithrombin Resistance by Yuhri Miyawaki, Atsuo Suzuki, Junko Fujita, Asuka Maki, Eriko Okuyama, Moe Murata, Akira Takagi, Takashi Murate, Shinji Kunishima, Michio Sakai, Kohji Okamoto, Tadashi Matsushita, Tomoki Naoe, Hidehiko Saito, Tetsuhito Kojima
Published 2012Artigo -
14
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice by Maimaiti Yisireyili, Motoharu Hayashi, Hongxian Wu, Yasuhiro Uchida, Koji Yamamoto, Ryosuke Kikuchi, Mohammad Shoaib Hamrah, Takayuki Nakayama, Xian Wu Cheng, Tadashi Matsushita, Shigeo Nakamura, Toshimitsu Niwa, Toyoaki Murohara, Kyosuke Takeshita
Published 2017Artigo -
15
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results by Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Víctor Jiménez‐Yuste, Kaan Kavaklı, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić‐Šalek, Johannes Oldenburg
Published 2019Artigo -
16
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors by Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Hermann Eichler, Víctor Jiménez‐Yuste, Kaan Kavaklı, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić‐Šalek, Johannes Oldenburg, Pratima Chowdary
Published 2022Artigo -
17
Identification of six novel MYH9 mutations and genotype–phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions by Shinji Kunishima, Tadashi Matsushita, Toshiya Kojima, N Amemiya, Y. M. Choi, Naoki Hosaka, M. Inoue, Jung Yh, S Mamiya, Kiyoshi Matsumoto, Yuji Miyajima, Guolong Zhang, Changgeng Ruan, Kazuto Saito, K S Song, H.-J. Yoon, T. Kamiya, Hajime Saito
Published 2001Artigo -
18
International consensus recommendations on the management of people with haemophilia B by Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d’Oiron, Cédric Hermans, Víctor Jiménez‐Yuste, Adriana Linares, Tadashi Matsushita, Simon McRae, Margareth C. Ozelo, Sean Platton, Darrel W. Stafford, Robert F. Sidonio, Andreas Tiede
Published 2022Revisão -
19
An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease by Ryosuke Kikuchi, Kazuto Nakamura, Susan MacLauchlan, Doan Thi-Minh Ngo, Ippei Shimizu, José J. Fuster, Yasufumi Katanasaka, Sumiko Yoshida, Yan Qiu, Terry P. Yamaguchi, Tadashi Matsushita, Toyoaki Murohara, Noyan Gokce, David O. Bates, Naomi M. Hamburg, Kenneth Walsh
Published 2014Artigo -
20
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extensio... by John Pasi, Kathelijn Fischer, Margaret V. Ragni, Roshni Kulkarni, Margareth C. Ozelo, Johnny Mahlangu, Amy D. Shapiro, Stephanie P’ng, Hérvè Chambost, Beatrice Nolan, Carolyn M. Bennett, Tadashi Matsushita, Bent Winding, Joachim Fruebis, Huixing Yuan, Dan Rudin, Johannes Oldenburg
Published 2020Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Immunology
Biology
Gene
Biochemistry
Surgery
Chemistry
Clinical trial
Endocrinology
Platelet
Antibody
Genetics
Pediatrics
Clinical endpoint
Factor IX
Haemophilia
Haemophilia A
Recombinant DNA
Amino acid
Antithrombin
Cell biology
Coagulation
Enzyme
Gastroenterology
Haemophilia B
Heparin
Thrombin
Von Willebrand factor
Adverse effect